Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.
The Ludwig Center for Metastasis Research, University of Chicago, Chicago, Illinois.
Clin Cancer Res. 2020 Jun 15;26(12):2777-2782. doi: 10.1158/1078-0432.CCR-19-2034. Epub 2020 Feb 11.
In the era of cancer immunotherapy, there is significant interest in combining conventional cancer therapies, such as radiotherapy, with drugs that stimulate the immune system. The observation that ionizing radiation applied to murine tumors delays the growth of distant tumors ("abscopal effect") and that this effect is potentiated by immunostimulatory drugs, led to clinical trials in which often only one lesion is irradiated in combination with immunotherapy drugs. The results of these initial clinical trials combining radio therapy and immunotherapy show that a meaningful abscopal effect is still infrequent. Recent preclinical data suggest that preexistent intratumoral T cells can survive radiation and contribute to its therapeutic effect. In this review, we discuss possible mechanisms underlying the preclinical/clinical discrepancies regarding the abscopal effect, and we propose the irradiation of multiple or all tumor sites in combination with systemic immunotherapy as a possible avenue to increase the efficacy of radio-immunotherapy.
在癌症免疫治疗时代,人们对将传统癌症疗法(如放射疗法)与刺激免疫系统的药物结合使用产生了浓厚的兴趣。观察到应用于鼠肿瘤的电离辐射会延迟远处肿瘤的生长(“远隔效应”),并且这种效应可以通过免疫刺激药物增强,这导致了临床试验,其中通常仅对一个病灶进行放射治疗,并与免疫治疗药物联合使用。这些结合放射治疗和免疫治疗的初步临床试验的结果表明,远隔效应仍然很少见。最近的临床前数据表明,肿瘤内的预先存在的 T 细胞可以在辐射下存活,并有助于其治疗效果。在这篇综述中,我们讨论了远隔效应的临床前/临床差异的可能机制,并提出了对多个或所有肿瘤部位进行放射治疗,并结合全身免疫治疗作为提高放射免疫治疗效果的一种可能途径。